US · Healthcare · Diagnostics & Research
EPS came in at 3.00 against a street estimate of 2.85 — a beat of 5.3%.
Analysts rate Quest Diagnostics Incorporated a buy (9 buy, 8 hold, 0 sell out of 17) with an average price target of $257.27.
CONFIDENT Quest delivered strong organic growth, raised 2026 guidance, and highlighted consumer, hospital, physician, AI and automation momentum. PAMA remains the key 2027 risk, while management expects partial offsets. Q3 FY26 No geographic revenue breakdown was provided. Analysts focused on unusually strong organic volumes, consumer and Apple Health ramp, margins, ACA enrollment, cybersecurity and PAMA. Management emphasized broad-based demand, productivity offsets and continued advocacy for the RESULTS Act. 2026-10-22…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.40% |
| Vanguard Capital Management, LLC | 6.55% |
| Vanguard Portfolio Management, LLC | 5.55% |
| State Street Corp | 5.00% |
| T. Rowe Price Associates, Inc. | 4.93% |
| Boston Partners Global Investors, Inc | 4.30% |
| JPMorgan Chase & Co | 3.19% |
| Geode Capital Management, LLC | 2.84% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $3,097 million, up from $2,816 million in the third quarter of 2025. • Nine-month 2026 net rev | 2026-10-23 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 21, 2026, Quest Diagnostics discovered unauthorized access to its Quanum LSM system. • The company currently believes | 2026-10-22 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $3.097 billion, up 10.0% from $2.816 billion in 2025. • Diagnostic Information Services revenue wa | 2026-10-22 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Quest Diagnostics announced that Catherine T. Doherty will retire in July 2027. • Effective November 1, 2026, Doherty will tr | 2026-10-06 |
| Quarterly report · Q2 2026 QUEST DIAGNOSTICS INC (DGX) - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $3,043 million (vs. $2,761 million in Q2 2025) — up 10.2% • S | 2026-07-23 |
| Results announced · Q3 2026 QUEST DIAGNOSTICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $3.04 billion, up 10.2% year-over-year; organic revenue growth 10.0% | 2026-07-23 |
| Shareholder vote results · Q2 2026 QUEST DIAGNOSTICS INC - DOCUMENT SUMMARY HEADLINE NUMBERS • Annual Meeting held May 20, 2026 • 11 directors elected to board for terms expiring at 2 | 2026-05-21 |
| Material agreement · Q2 2026 QUEST DIAGNOSTICS INCORPORATED — FORM 8-K SUMMARY HEADLINE NUMBERS • Quest Diagnostics issued $500,000,000 in senior notes on May 6, 2026 • Interest | 2026-05-08 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.86 / share ex-date Oct 6, 2026 · pay Oct 21, 2026 | 2026-10-06 |
| Dividend | $0.86 / share ex-date Jul 8, 2026 · pay Jul 22, 2026 | 2026-07-08 |
| Dividend | $0.86 / share ex-date Apr 6, 2026 · pay Apr 20, 2026 | 2026-04-06 |
| Dividend | $0.80 / share ex-date Jan 13, 2026 · pay Jan 28, 2026 | 2026-01-13 |
| Dividend | $0.80 / share ex-date Oct 3, 2025 · pay Oct 20, 2025 | 2025-10-03 |
| Announcement | Date |
|---|---|
| Board authorizes $1B stock repurchase; quarterly dividend raised 7.5% Quest Diagnostics announced its Q4 2025 and full-year 2025 financial results on February 10, 2026. Along with the earnings announcement, the company's Board of Directors made two shareholder | 2026-02-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quest Diagnostics Incorporated — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.